ERBB2 and breast carcinoma: Several studies have also found that activation of Src causes lapatinib resistance [35, 36], more specifically activated Src is upregulated in β1-integrin- and mTORC1-mediated resistance to lapatinib in erbB2-positive breast cancer cells [37, 38].